UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2021
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
||
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
||
|
|
||||
|
(Address of Principal Executive Offices) (Zip Code)
|
||||
|
(
|
||||
|
(Registrant’s telephone number, including area code)
|
||||
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 – Results of Operations and Financial Condition.
On March 30, 2021, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal third
quarter ended February 28, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 – Regulation FD Disclosure.
Presentation slides discussing AngioDynamics and its fiscal third quarter ended February 28, 2021 are furnished herewith as Exhibit
99.2.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange
Act.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “project”, “optimistic,” or variations of such words and
similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially
from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical
trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product
liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate
fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but
not limited to its Annual Report on Form 10-K for the year ended May 31, 2020 and its Quarterly Reports on Form 10-Q for the fiscal periods ended August 31, 2020 and November 30, 2020. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press Release, dated March 30, 2021.
|
||
|
Presentation, dated March 30, 2021.
|
||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
| ANGIODYNAMICS, INC. | |||
| (Registrant) |
|||
|
Date: March 30, 2021
|
By:
|
/s/ Stephen A. Trowbridge | |
| Name: Stephen A. Trowbridge | |||
|
Title: Executive Vice President and
Chief Financial Officer
|
|||
Exhibit 99.1
PRESS RELEASE
Investor Contact:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance
Fiscal 2021 Third Quarter Highlights
|
•
|
Net sales of $71.2 million increased 2.0% compared to the prior-year quarter
|
|
•
|
Gross margin of 54.1%, a decline of 370 basis points year over year
|
|
•
|
GAAP loss per share of $0.09 and adjusted earnings per share of $0.02
|
|
•
|
Cash and cash equivalents on February 28, 2021 were $54.5 million
|
|
•
|
The Company is raising its fiscal year 2021 guidance. The Company now expects net sales between $285 and $288
million and fiscal year 2021 adjusted earnings per share between $0.04 and $0.06
|
Latham, New York, March 30, 2021 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading
provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the third quarter of fiscal year 2021, which ended February 28, 2021.
“I am pleased with our strong third quarter performance, driven by continued strength in our AngioVac and Auryon platforms. Our revenue grew 2%
year over year despite continued COVID-19 headwinds, particularly in January and the first half of February. Further, we are encouraged by the recent improvements in our end markets and increasing availability of vaccines,” commented Jim Clemmer,
President and Chief Executive Officer of AngioDynamics, Inc. “We continue to execute on our strategy to drive revenue growth through our key technology platforms: Auryon, AngioVac, and NanoKnife. In addition, our balanced approach to cash and expense
management continues to yield profitability on an adjusted basis while allowing us to invest in the development and progression of these key platforms. I am excited about the planned
launch of our new mechanical thrombectomy device later in calendar 2021, as well as a number of other planned product improvements and clinical
and regulatory pathway expansions that will open up opportunities for us in larger, higher-growth markets.”
Third Quarter 2021 Financial Results
Net sales for the third quarter of fiscal 2021 were $71.2 million, an
increase of 2.0% compared to the prior-year quarter. Net sales in the third quarter continued to be impacted by the disruption to procedure volumes resulting from the COVID-19 global pandemic. Foreign currency translation did not have a significant
impact on the Company's sales in the quarter.
• Vascular Interventions and Therapies (“VIT”) net sales were
$33.3 million, an increase of 8.8%, compared to $30.6 million a year ago. Growth was driven primarily by increased sales of the Company's Auryon and AngioVac platforms compared to the previous year. This growth was partially offset by a decline in sales of Venous products resulting from a decline in
elective procedure volumes due to the ongoing COVID-19 global pandemic. Auryon sales during the quarter were $3.3 million.
• Oncology net sales were $13.1 million, a decrease of 10.1% from $14.6 million in the prior-year period. The year-over-year decline was primarily attributable to lower
capital sales and ongoing procedure impacts of COVID-19, particularly in international markets, partially offset by continued growth in sales of NanoKnife disposables in the United States.
• Vascular Access net sales were $24.8 million, compared to $24.6 million a year ago.
U.S. net sales in the third quarter of fiscal 2021 were $58.7 million, an increase of 6.9% from $54.9 million a year ago. International net sales
were $12.5 million in the third quarter of fiscal 2021 compared to $14.9 million a year ago.
Gross margin for the third quarter of fiscal 2021 was 54.1%, a decline
of 370 basis points compared to the third quarter of fiscal 2020. Consistent with the first half of the year, the year-over-year decline in gross margin was primarily due to Auryon start-up costs and the Company's previously discussed COVID-related operating plan, including under-absorption of the
Company's manufacturing facilities attributable to
additional operating protocols designed to secure the supply-chain and prioritize employee safety. In addition, gross margin was negatively impacted by staffing challenges in the Company's upstate New York manufacturing facility. During the third quarter, inventory was reduced by $0.6 million
when compared to inventory levels on November 30, 2020. During the fiscal year, inventory levels have been reduced by $10.9 million.
The Company recorded a net loss of $3.5 million, or loss per share of $0.09, in the third quarter of fiscal 2021. This compares to a net loss of
$5.7 million, or loss per share of $0.15, a year ago.
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income for the third quarter of fiscal 2021 was $0.7 million,
and adjusted earnings per share was $0.02, compared to adjusted net income in the prior-year period of $0.4 million and adjusted earnings per share of $0.01. Adjusted net income and adjusted earnings per share in the third quarter of fiscal 2021
includes a $1.9 million, and $0.04 per share benefit, respectively, related to the reimbursement of certain expenses under the CARES Act.
Adjusted EBITDA in the third quarter of fiscal 2021, excluding the items shown in the reconciliation table below, was $5.4 million, compared to
$3.8 million in the third quarter of fiscal 2020.
In the third quarter of fiscal 2021, the Company generated $5.9 million in operating cash and had capital expenditures of $1.4 million. As of
February 28, 2021, the Company had $54.5 million in cash and cash equivalents compared to $58.0 million in cash and cash equivalents on November 30, 2020. The Company reduced its debt outstanding under its revolving credit facility at February 28,
2021, to $30.0 million compared to $40.0 million at November 30, 2020. Subsequent to the end of the third fiscal quarter, the Company further reduced debt outstanding under the revolving credit facility to $20 million. Management remains focused on
cash preservation and expense management amid the current environment.
Nine Months Financial Results
For the nine months ended February 28, 2021:
|
•
|
Net sales were $214.2 million, an increase of 4.1%, compared to $205.8 million for the same period a year ago.
|
|
•
|
The Company's net loss was $12.1 million, or a loss of $0.32 per share, compared to a net loss of $9.7 million, or a loss of $0.26 per
share, a year ago.
|
|
•
|
Gross margin decreased 490 basis points to 53.4% from 58.3% a
year ago due to the Company's COVID-related operating plan and Auryon start-up costs.
|
|
•
|
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net income was $1.9 million, with adjusted earnings per
share of $0.05, compared to adjusted net income and adjusted earnings per share of $5.7 million, and $0.15, respectively, a year ago.
|
|
•
|
Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $15.0 million, compared to $17.5 million for the same
period a year ago.
|
Fiscal Year 2021 Financial Guidance
The Company is increasing its guidance for fiscal year 2021. Management now projects net sales between $285 and $288 million and fiscal year 2021
adjusted earnings per share between $0.04 and $0.06, compared to previous projections of net sales between $278 and $284 million and adjusted earnings per share between $0.00 and $0.05.
Conference Call
The Company's management will host a conference call today at 8:00 a.m. ET to discuss its fiscal 2021 third quarter
results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13717367.
This conference call will also be webcast and can be accessed from the
“Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available from 11:00 a.m. ET on Tuesday, March 30, 2021, until 11:59 p.m. ET on Tuesday, April 6, 2021. To
hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13717367.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the
underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release,
AngioDynamics has reported adjusted EBITDA, adjusted net income, adjusted earnings per share, and free cash flow. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures
provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying
business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to
time but have a material
impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in
accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative, minimally
invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic
products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from
AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical
trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product
liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate
fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but
not limited to its Annual Report on Form 10-K for the year ended May 31, 2020. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation
of soft tissue and is similarly approved for commercialization in Canada, the European Union, and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED INCOME STATEMENTS
|
|
(in thousands, except per share data)
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net sales
|
$
|
71,182
|
$
|
69,780
|
$
|
214,168
|
$
|
205,825
|
|||||||
|
Cost of sales (exclusive of intangible amortization)
|
32,652
|
29,481
|
99,700
|
85,765
|
|||||||||||
|
Gross profit
|
38,530
|
40,299
|
114,468
|
120,060
|
|||||||||||
|
% of net sales
|
54.1
|
%
|
57.8
|
%
|
53.4
|
%
|
58.3
|
%
|
|||||||
|
Operating expenses
|
|||||||||||||||
|
Research and development
|
8,565
|
8,395
|
27,286
|
22,450
|
|||||||||||
|
Sales and marketing
|
19,607
|
20,934
|
57,486
|
60,427
|
|||||||||||
|
General and administrative
|
9,011
|
10,203
|
26,787
|
29,651
|
|||||||||||
|
Amortization of intangibles
|
4,292
|
5,019
|
13,838
|
13,417
|
|||||||||||
|
Change in fair value of contingent consideration
|
183
|
419
|
(290)
|
116
|
|||||||||||
|
Acquisition, restructuring and other items, net
|
610
|
1,565
|
3,057
|
4,486
|
|||||||||||
|
Total operating expenses
|
42,268
|
46,535
|
128,164
|
130,547
|
|||||||||||
|
Operating loss
|
(3,738)
|
(6,236)
|
(13,696)
|
(10,487)
|
|||||||||||
|
Interest expense, net
|
(226)
|
(166)
|
(676)
|
(672)
|
|||||||||||
|
Other income (expense), net
|
(163)
|
(131)
|
259
|
(67)
|
|||||||||||
|
Total other expense, net
|
(389)
|
(297)
|
(417)
|
(739)
|
|||||||||||
|
Loss before income tax benefit
|
(4,127)
|
(6,533)
|
(14,113)
|
(11,226)
|
|||||||||||
|
Income tax benefit
|
(583)
|
(824)
|
(2,033)
|
(1,506)
|
|||||||||||
|
Net loss
|
$
|
(3,544)
|
$
|
(5,709)
|
$
|
(12,080)
|
$
|
(9,720)
|
|||||||
|
Loss per share
|
|||||||||||||||
|
Basic
|
$
|
(0.09)
|
$
|
(0.15)
|
$
|
(0.32)
|
$
|
(0.26)
|
|||||||
|
Diluted
|
$
|
(0.09)
|
$
|
(0.15)
|
$
|
(0.32)
|
$
|
(0.26)
|
|||||||
|
Weighted average shares outstanding
|
|||||||||||||||
|
Basic
|
38,360
|
37,999
|
38,281
|
37,924
|
|||||||||||
|
Diluted
|
38,360
|
37,999
|
38,281
|
37,924
|
|||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Loss to non-GAAP Adjusted Net Income:
|
|||||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net loss
|
$
|
(3,544)
|
$
|
(5,709)
|
$
|
(12,080)
|
$
|
(9,720)
|
|||||||
|
Amortization of intangibles
|
4,292
|
5,019
|
13,838
|
13,417
|
|||||||||||
|
Change in fair value of contingent consideration
|
183
|
419
|
(290)
|
116
|
|||||||||||
|
Acquisition, restructuring and other items, net (1)
|
610
|
1,565
|
3,057
|
4,486
|
|||||||||||
|
Write-off of deferred financing fees (2)
|
—
|
—
|
—
|
593
|
|||||||||||
|
Tax effect of non-GAAP items (3)
|
(803)
|
(932)
|
(2,606)
|
(3,205)
|
|||||||||||
|
Adjusted net income
|
$
|
738
|
$
|
362
|
$
|
1,919
|
$
|
5,687
|
|||||||
|
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings Per Share:
|
|||||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Diluted loss per share
|
$
|
(0.09)
|
$
|
(0.15)
|
$
|
(0.32)
|
$
|
(0.26)
|
|||||||
|
Amortization of intangibles
|
0.11
|
0.13
|
0.36
|
0.35
|
|||||||||||
|
Change in fair value of contingent consideration
|
—
|
0.01
|
(0.01)
|
—
|
|||||||||||
|
Acquisition, restructuring and other items, net (1)
|
0.02
|
0.04
|
0.08
|
0.12
|
|||||||||||
|
Write-off of deferred financing fees (2)
|
—
|
—
|
—
|
0.02
|
|||||||||||
|
Tax effect of non-GAAP items (3)
|
(0.02)
|
(0.02)
|
(0.06)
|
(0.08)
|
|||||||||||
|
Adjusted diluted earnings per share
|
$
|
0.02
|
$
|
0.01
|
$
|
0.05
|
$
|
0.15
|
|||||||
|
Adjusted diluted sharecount (4)
|
39,271
|
38,094
|
38,770
|
38,111
|
|||||||||||
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and
write-offs, certain litigation, and other items.
|
|
(2) Deferred financing fees related to the old credit agreement were written off during the first quarter of fiscal year 2020.
|
|
(3) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred
tax assets and an effective tax rate of 23% for the periods ended February 28, 2021 and February 29, 2020.
|
|
(4) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
|
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION (Continued)
|
|
(in thousands, except per share data)
|
|
Reconciliation of Net Loss to Adjusted EBITDA:
|
|||||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net loss
|
$
|
(3,544)
|
$
|
(5,709)
|
$
|
(12,080)
|
$
|
(9,720)
|
|||||||
|
Income tax benefit
|
(583)
|
(824)
|
(2,033)
|
(1,506)
|
|||||||||||
|
Interest expense, net
|
226
|
166
|
676
|
672
|
|||||||||||
|
Depreciation and amortization
|
6,340
|
6,401
|
19,276
|
17,434
|
|||||||||||
|
Change in fair value of contingent consideration
|
183
|
419
|
(290)
|
116
|
|||||||||||
|
Stock based compensation
|
2,147
|
1,772
|
6,398
|
5,998
|
|||||||||||
|
Acquisition, restructuring and other items, net (1)
|
610
|
1,565
|
3,057
|
4,486
|
|||||||||||
|
Adjusted EBITDA
|
$
|
5,379
|
$
|
3,790
|
$
|
15,004
|
$
|
17,480
|
|||||||
|
Per diluted share:
|
|||||||||||||||
|
Adjusted EBITDA
|
$
|
0.14
|
$
|
0.10
|
$
|
0.39
|
$
|
0.46
|
|||||||
|
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and
write-offs, certain litigation, and other items.
|
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
|
|
(in thousands)
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
% Growth
|
Currency Impact
|
Constant Currency Growth
|
Feb 28, 2021
|
Feb 29, 2020
|
% Growth
|
Currency Impact
|
Constant Currency Growth
|
||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||||||||||||||
|
Net Sales by Product Category
|
|||||||||||||||||||||||||||
|
Vascular Interventions & Therapies
|
$
|
33,251
|
$
|
30,552
|
8.8%
|
$
|
97,008
|
$
|
90,616
|
7.1%
|
|||||||||||||||||
|
Vascular Access
|
24,813
|
24,642
|
0.7%
|
76,848
|
70,585
|
8.9%
|
|||||||||||||||||||||
|
Oncology
|
13,118
|
14,586
|
(10.1)%
|
40,312
|
44,624
|
(9.7)%
|
|||||||||||||||||||||
|
$
|
71,182
|
$
|
69,780
|
2.0%
|
(0.4)%
|
1.6%
|
$
|
214,168
|
$
|
205,825
|
4.1%
|
(0.3)%
|
3.8%
|
||||||||||||||
|
—
|
—
|
||||||||||||||||||||||||||
|
Net Sales by Geography
|
|||||||||||||||||||||||||||
|
United States
|
$
|
58,654
|
$
|
54,889
|
6.9%
|
$
|
173,446
|
$
|
163,381
|
6.2%
|
|||||||||||||||||
|
International
|
12,528
|
14,891
|
(15.9)%
|
(2.1)%
|
(18.0)%
|
40,722
|
42,444
|
(4.1)%
|
(1.2)%
|
(5.3)%
|
|||||||||||||||||
|
$
|
71,182
|
$
|
69,780
|
2.0%
|
(0.4)%
|
1.6%
|
$
|
214,168
|
$
|
205,825
|
4.1%
|
(0.3)%
|
3.8%
|
||||||||||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED BALANCE SHEETS
|
|
(in thousands)
|
|
Feb 28, 2021
|
May 31, 2020
|
||||||
|
(unaudited)
|
(audited)
|
||||||
|
Assets
|
|||||||
|
Current assets:
|
|||||||
|
Cash and cash equivalents
|
$
|
54,469
|
$
|
54,435
|
|||
|
Accounts receivable, net
|
33,171
|
31,263
|
|||||
|
Inventories
|
49,006
|
59,905
|
|||||
|
Prepaid expenses and other
|
9,011
|
7,310
|
|||||
|
Total current assets
|
145,657
|
152,913
|
|||||
|
Property, plant and equipment, net
|
29,827
|
28,312
|
|||||
|
Other assets
|
19,443
|
15,338
|
|||||
|
Intangible assets, net
|
186,216
|
197,136
|
|||||
|
Goodwill
|
201,102
|
200,515
|
|||||
|
Total assets
|
$
|
582,245
|
$
|
594,214
|
|||
|
Liabilities and stockholders' equity
|
|||||||
|
Current liabilities:
|
|||||||
|
Accounts payable
|
$
|
17,067
|
$
|
19,096
|
|||
|
Accrued liabilities
|
30,760
|
29,380
|
|||||
|
Current portion of contingent consideration
|
—
|
836
|
|||||
|
Other current liabilities
|
2,429
|
2,133
|
|||||
|
Total current liabilities
|
50,256
|
51,445
|
|||||
|
Long-term debt, net of current portion
|
30,000
|
40,000
|
|||||
|
Deferred income taxes
|
22,371
|
24,057
|
|||||
|
Contingent consideration, net of current portion
|
15,362
|
14,811
|
|||||
|
Other long-term liabilities
|
9,320
|
9,029
|
|||||
|
Total liabilities
|
127,309
|
139,342
|
|||||
|
Stockholders' equity
|
454,936
|
454,872
|
|||||
|
Total Liabilities and Stockholders' Equity
|
$
|
582,245
|
$
|
594,214
|
|||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(in thousands)
|
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Cash flows from operating activities:
|
|||||||||||||||
|
Net loss
|
$
|
(3,544)
|
$
|
(5,709)
|
$
|
(12,080)
|
$
|
(9,720)
|
|||||||
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
|||||||||||||||
|
Depreciation and amortization
|
6,379
|
6,440
|
19,392
|
17,550
|
|||||||||||
|
Non-cash lease expense
|
595
|
663
|
1,860
|
1,567
|
|||||||||||
|
Stock based compensation
|
2,147
|
1,772
|
6,398
|
5,998
|
|||||||||||
|
Change in fair value of contingent consideration
|
183
|
419
|
(290)
|
116
|
|||||||||||
|
Deferred income taxes
|
(634)
|
(872)
|
(2,187)
|
(1,606)
|
|||||||||||
|
Change in accounts receivable allowances
|
2
|
(13)
|
31
|
186
|
|||||||||||
|
Fixed and intangible asset impairments and disposals
|
10
|
26
|
190
|
395
|
|||||||||||
|
Write-off of other assets
|
—
|
—
|
—
|
593
|
|||||||||||
|
Other
|
81
|
97
|
(149)
|
70
|
|||||||||||
|
Changes in operating assets and liabilities, net of acquisitions:
|
|||||||||||||||
|
Accounts receivable
|
458
|
(1,630)
|
(1,823)
|
7,834
|
|||||||||||
|
Inventories
|
591
|
(4,027)
|
11,119
|
(14,036)
|
|||||||||||
|
Prepaid expenses and other
|
(2,498)
|
(5,834)
|
(8,821)
|
(9,378)
|
|||||||||||
|
Accounts payable, accrued and other liabilities
|
2,101
|
(9,169)
|
(1,746)
|
(18,003)
|
|||||||||||
|
Net cash provided by (used in) operating activities
|
5,871
|
(17,837)
|
11,894
|
(18,434)
|
|||||||||||
|
Cash flows from investing activities:
|
|||||||||||||||
|
Additions to property, plant and equipment
|
(1,382)
|
(1,742)
|
(4,567)
|
(5,756)
|
|||||||||||
|
Acquisition of intangibles
|
—
|
—
|
—
|
(350)
|
|||||||||||
|
Cash paid in acquisition
|
—
|
(10,000)
|
—
|
(55,760)
|
|||||||||||
|
Net cash used in investing activities
|
(1,382)
|
(11,742)
|
(4,567)
|
(61,866)
|
|||||||||||
|
Cash flows from financing activities:
|
|||||||||||||||
|
Proceeds from borrowings on long-term debt
|
—
|
15,000
|
—
|
15,000
|
|||||||||||
|
Repayment of long-term debt
|
(10,000)
|
—
|
(10,000)
|
(132,500)
|
|||||||||||
|
Deferred financing costs on long-term debt
|
—
|
(34)
|
—
|
(775)
|
|||||||||||
|
Payment of acquisition related contingent consideration
|
—
|
—
|
—
|
(1,208)
|
|||||||||||
|
Proceeds (outlays) from exercise of stock options and employee stock purchase plan
|
1,978
|
594
|
2,459
|
(706)
|
|||||||||||
|
Net cash provided by (used in) financing activities
|
(8,022)
|
15,560
|
(7,541)
|
(120,189)
|
|||||||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
(23)
|
(68)
|
248
|
8
|
|||||||||||
|
Increase (decrease) in cash and cash equivalents
|
(3,556)
|
(14,087)
|
34
|
(200,481)
|
|||||||||||
|
Cash and cash equivalents at beginning of period
|
58,025
|
41,247
|
54,435
|
227,641
|
|||||||||||
|
Cash and cash equivalents at end of period
|
$
|
54,469
|
$
|
27,160
|
$
|
54,469
|
$
|
27,160
|
|||||||
|
ANGIODYNAMICS, INC. AND SUBSIDIARIES
|
|
GAAP TO NON-GAAP RECONCILIATION
|
|
(in thousands)
|
|
Reconciliation of Free Cash Flows:
|
|||||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
||||||||||||||
|
Feb 28, 2021
|
Feb 29, 2020
|
Feb 28, 2021
|
Feb 29, 2020
|
||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||
|
Net cash provided by (used in) operating activities
|
$
|
5,871
|
$
|
(17,837)
|
$
|
11,894
|
$
|
(18,434)
|
|||||||
|
Additions to property, plant and equipment
|
(1,382)
|
(1,742)
|
(4,567)
|
(5,756)
|
|||||||||||
|
Free Cash Flow
|
$
|
4,489
|
$
|
(19,579)
|
$
|
7,327
|
$
|
(24,190)
|
|||||||
Exhibit 99.2
ANGIODYNAMICS Third Quarter 2021 Earnings PresentationMarch 30, 2021 1
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets,
projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,”
“anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics
include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’
technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or
other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to
third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition,
the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2020.
AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in
the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.Notice
Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors
should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before
interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management
believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance
of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including
those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
Corporate Developments – Q3 Highlights 3 27% Growth in AngioVac $3.3 million in
Auryon sales NanoKnife disposable growth: US 12% YOY; worldwide decline of 7% YOY Procedural volumes negatively impacted in January and first half of February Began to rebound in the second half of FebruaryAngioVac and Auryon procedure volume
exhibited resiliency in Q3 Continued focused investment in our 3 key technology platforms: Auryon, AngioVac & NanoKnife NanoKnife DIRECT study: 22 sites have secured IRB approval, down 4 from Q2 Decommissioned 4 sites to continue to
refine and optimize the processWe are encouraged by the overall execution of the study in the current environment Revised FY2021 Guidance RevenuePrevious Guidance Revised Guidance Adjusted EPSPrevious Guidance Revised Guidance Reduced
debt outstanding under revolver by $20 million as of March 2021 Completed enrollment of PATHFINDER 1 pilot registry Shifting our focus to the pivotal study phase $278 - $284 mil $285 - $288 mil $0.00 - $0.05 $0.04 - $0.06 Recognized a
$1.9 million benefit to net income in Q3 from the CARES Act
Third Quarter FY2021 Highlights $ in thousands (except per share data) Q3 FY2021 Q3 FY2020 YOY
Change Revenue $71,182 $69,780 2.0% Gross Margin 54.1% 57.8% (370 bps) Net Loss ($3,544) ($5,709) $2,165 GAAP EPS ($0.09) ($0.15) $0.06 Adjusted EPS $0.02 $0.01 $0.01 Adjusted EBITDA $5,379 $3,790 $1,589 Cash Provided
by (Used in) Operations $5,871 ($17,837) $23,708 Financial Performance Vascular Interventions and Therapies Q3 FY2021 YTD FY2021 AngioVac® 27% 31% Auryon NA* NA* Thrombolytic 2% (1%) Core Peripheral (5%) (1%) Venous
Insufficiency (16%) (14%) Product Family Sales Growth Over Prior Year Periods Vascular Access Q3 FY2021 YTD FY2021 Midlines 16% 40% C3 10% NA** PICCs (3%) 14% Ports (2%) (1%) Dialysis 2% 2% Oncology Q3 FY2021 YTD
FY2021 NanoKnife® Capital (5%) (40%) NanoKnife® Disposables (7%) 4% Solero® Microwave (4%) 3% BioSentry 17% 24% Alatus and IsoLoc Balloons (18%) (24%) RadioFrequency Ablation (24%) (24%) * The Auryon full market launch took
place in the second quarter of fiscal year 2021.** The C3 Wave acquisition took place in December 2019.
Third Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q3 FY2021 Q3
FY2020 Change YTD FY2021 YTD FY2020 Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States
International $71,182$33,251$24,813$13,118$58,654$12,528 $69,780$30,552$24,642$14,586$54,889$14,891 2.0%8.8%0.7%(10.1%)6.9%(15.9%) $214,168$97,008$76,848$40,312$173,446$40,722 $205,825$90,616$70,585$44,624$163,381$42,444 4.1%7.1%8.9%(9.7%)6.2%(4.1%) Net
LossNon-GAAP Adjusted Net Income ($3,544)$738 ($5,709)$362 $2,165$376 ($12,080)$1,919 ($9,720)$5,687 ($2,360)($3,768) GAAP EPSNon-GAAP Adjusted
EPS ($0.09)$0.02 ($0.15)$0.01 $0.06$0.01 ($0.32)$0.05 ($0.26)$0.15 ($0.06)($0.10) Gross Margin 54.1% 57.8% (370 bps) 53.4% 58.3% (490 bps) Adjusted EBITDA $5,379 $3,790 $1,589 $15,004 $17,480 ($2,476) $ in thousands (except
per share data) Q3 FY2021 Q4 FY2020 Change Cash $54,469 $54,435 $34 Debt $30,000* $40,000 ($10,000) 5 * In March 2021, another $10 million was paid on the revolver. Total debt outstanding is now $20 million.
GAAP to Non-GAAP Reconciliation 6
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted
EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old credit agreement
were written off during the second quarter of fiscal year 2020.Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an effective tax
rate of 23% for the periods ended February 28, 2021 and February 29, 2020.Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss. 7 Includes costs related to merger and acquisition activities, restructurings,
and unusual items, including asset impairments and write-offs, certain litigation, and other items. (in thousands, except per share data) (in thousands)
8